Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Double Blind Randomized Placebo Controlled Trial of Adjunctive




 

Heart Online (heart.bmjjournals.com) (08/00) Vol. 84, No. 2,

Researchers from Zimbabwe conducted a study to determine how adjunctive prednisolone affects the morbidity, pericardial fluid resolution, and mortality of HIV-seropositive patients with effusive tuberculous pericarditis. The study involved 58 patients between the ages of 18 and 55. Following a short course of antituberculous chemotherapy, the patients received treatment with prednisolone or placebo for six weeks. After 18 months, five patients who took prednisolone and 10 patients who took placebo had died. According to the researchers, patients randomized to receive prednisolone achieved a significantly quicker resolution of increased jugular venous pressure, hepatomegaly, and ascites. However, they note that the rate of radiologic and echocardiographic resolution of pericardial effusion was comparable in both groups.



 


Copyright © 2000 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in August 24, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.